BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis
USA - NASDAQ:BMRN - US09061G1013 - Common Stock
53.94 USD
+0.8 (+1.51%)
53.4 USD
-0.54 (-1%)
We assign a fundamental rating of 6 out of 10 to BMRN. BMRN was compared to 540 industry peers in the Biotechnology industry. BMRN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BMRN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make BMRN suitable for value and quality investing!
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
In the past year BMRN had a positive cash flow from operations.
BMRN had positive earnings in 4 of the past 5 years.
In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.81%, BMRN belongs to the top of the industry, outperforming 93.15% of the companies in the same industry.
The Return On Equity of BMRN (10.90%) is better than 93.15% of its industry peers.
BMRN has a better Return On Invested Capital (10.27%) than 94.26% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BMRN is significantly below the industry average of 15.95%.
The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(10.27%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.81% | ||
| ROE | 10.9% | ||
| ROIC | 10.27% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
BMRN has a Profit Margin of 21.45%. This is amongst the best in the industry. BMRN outperforms 94.81% of its industry peers.
The Operating Margin of BMRN (27.07%) is better than 96.11% of its industry peers.
BMRN has a Gross Margin of 79.56%. This is amongst the best in the industry. BMRN outperforms 84.63% of its industry peers.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.07% | ||
| PM (TTM) | 21.45% | ||
| GM | 79.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BMRN is creating some value.
BMRN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BMRN has been increased compared to 5 years ago.
BMRN has a better debt/assets ratio than last year.
2.2 Solvency
BMRN has an Altman-Z score of 5.67. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BMRN (5.67) is better than 77.41% of its industry peers.
BMRN has a debt to FCF ratio of 0.86. This is a very positive value and a sign of high solvency as it would only need 0.86 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.86, BMRN belongs to the top of the industry, outperforming 95.00% of the companies in the same industry.
BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
BMRN has a worse Debt to Equity ratio (0.10) than 64.26% of its industry peers.
Although BMRN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.86 | ||
| Altman-Z | 5.67 |
ROIC/WACC1.11
WACC9.28%
2.3 Liquidity
BMRN has a Current Ratio of 5.56. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.56, BMRN is in line with its industry, outperforming 59.81% of the companies in the same industry.
BMRN has a Quick Ratio of 3.60. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BMRN (3.60) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.56 | ||
| Quick Ratio | 3.6 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 139.01% over the past year.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.36%.
The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)139.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%119.64%
Revenue 1Y (TTM)18.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%15.92%
3.2 Future
BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.47% yearly.
BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.65% yearly.
EPS Next Y57.89%
EPS Next 2Y41.83%
EPS Next 3Y33.62%
EPS Next 5Y28.47%
Revenue Next Year12.45%
Revenue Next 2Y10.88%
Revenue Next 3Y9.73%
Revenue Next 5Y7.65%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.01, the valuation of BMRN can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 95.19% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of BMRN to the average of the S&P500 Index (27.20), we can say BMRN is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 12.13, the valuation of BMRN can be described as correct.
BMRN's Price/Forward Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 96.30% of the companies in the same industry.
BMRN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.71.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.01 | ||
| Fwd PE | 12.13 |
4.2 Price Multiples
BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMRN is cheaper than 96.48% of the companies in the same industry.
BMRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMRN is cheaper than 96.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.98 | ||
| EV/EBITDA | 10.19 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 33.62% in the coming years.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y41.83%
EPS Next 3Y33.62%
5. Dividend
5.1 Amount
No dividends for BMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
53.94
+0.8 (+1.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.84%
Inst Owner Change-0.35%
Ins Owners0.66%
Ins Owner Change7.95%
Market Cap10.36B
Analysts83.53
Price Target98.18 (82.02%)
Short Float %3.13%
Short Ratio2.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.96%
Min EPS beat(2)31.48%
Max EPS beat(2)44.44%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)4.22%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)18.75%
EPS beat(12)9
Avg EPS beat(12)-3.48%
EPS beat(16)13
Avg EPS beat(16)0.88%
Revenue beat(2)1
Avg Revenue beat(2)2.55%
Min Revenue beat(2)-1.37%
Max Revenue beat(2)6.48%
Revenue beat(4)3
Avg Revenue beat(4)3.05%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.05%
Revenue beat(12)5
Avg Revenue beat(12)0.21%
Revenue beat(16)7
Avg Revenue beat(16)-0.31%
PT rev (1m)0.49%
PT rev (3m)0.33%
EPS NQ rev (1m)-0.45%
EPS NQ rev (3m)-29.26%
EPS NY rev (1m)-0.88%
EPS NY rev (3m)0.95%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-1.45%
Revenue NY rev (1m)0.87%
Revenue NY rev (3m)0.97%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.01 | ||
| Fwd PE | 12.13 | ||
| P/S | 3.38 | ||
| P/FCF | 14.98 | ||
| P/OCF | 13.51 | ||
| P/B | 1.72 | ||
| P/tB | 1.85 | ||
| EV/EBITDA | 10.19 |
EPS(TTM)3.37
EY6.25%
EPS(NY)4.45
Fwd EY8.24%
FCF(TTM)3.6
FCFY6.67%
OCF(TTM)3.99
OCFY7.4%
SpS15.96
BVpS31.39
TBVpS29.12
PEG (NY)0.28
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.81% | ||
| ROE | 10.9% | ||
| ROCE | 12.25% | ||
| ROIC | 10.27% | ||
| ROICexc | 13.02% | ||
| ROICexgc | 14.18% | ||
| OM | 27.07% | ||
| PM (TTM) | 21.45% | ||
| GM | 79.56% | ||
| FCFM | 22.56% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score7
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.86 | ||
| Debt/EBITDA | 0.65 | ||
| Cap/Depr | 90.83% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 93.49 | ||
| Cash Conversion | 84.01% | ||
| Profit Quality | 105.16% | ||
| Current Ratio | 5.56 | ||
| Quick Ratio | 3.6 | ||
| Altman-Z | 5.67 |
F-Score7
WACC9.28%
ROIC/WACC1.11
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)139.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%119.64%
EPS Next Y57.89%
EPS Next 2Y41.83%
EPS Next 3Y33.62%
EPS Next 5Y28.47%
Revenue 1Y (TTM)18.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%15.92%
Revenue Next Year12.45%
Revenue Next 2Y10.88%
Revenue Next 3Y9.73%
Revenue Next 5Y7.65%
EBIT growth 1Y198.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year99.59%
EBIT Next 3Y41.32%
EBIT Next 5Y23.56%
FCF growth 1Y1589.89%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y375.67%
OCF growth 3Y23.45%
OCF growth 5Y63.99%